SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Makers Laboratories - Quaterly Results

27 May 2026 Evaluate
The revenue for the March 2026 quarter is pegged at Rs. 112.75 millions, about 16.23% up against Rs. 97.01 millions recorded during the year-ago period.The Net Loss for the quarter ended March 2026 is Rs. -9.64 millions as compared to Net Loss of Rs. -14.00 millions of corresponding quarter ended March 2025 Operating profit Margin for the quarter ended March 2026 improved to -3.47% as compared to -11.86% of corresponding quarter ended March 2025


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 112.75 97.01 16.23 503.47 429.45 17.24 503.47 429.45 17.24
Other Income 0.25 0.25 0.00 5.93 109.24 -94.57 5.93 109.24 -94.57
PBIDT -3.47 -11.86 -70.74 13.23 87.15 -84.82 13.23 87.15 -84.82
Interest 1.23 0.92 33.70 5.31 9.40 -43.51 5.31 9.40 -43.51
PBDT -4.70 -12.78 -63.22 7.92 77.75 -89.81 7.92 77.75 -89.81
Depreciation 6.92 6.92 0.00 28.04 28.46 -1.48 28.04 28.46 -1.48
PBT -11.62 -19.70 -41.02 -20.12 49.29 -140.82 -20.12 49.29 -140.82
TAX -1.98 -5.70 -65.26 -2.92 2.87 -201.74 -2.92 2.87 -201.74
Deferred Tax -1.98 -5.69 -65.20 -2.92 2.88 -201.39 -2.92 2.88 -201.39
PAT -9.64 -14.00 -31.14 -17.20 46.42 -137.05 -17.20 46.42 -137.05
Equity 59.00 59.00 0.00 59.00 59.00 0.00 59.00 59.00 0.00
PBIDTM(%) -3.08 -12.23 -74.83 2.63 20.29 -87.05 2.63 20.29 -87.05

Makers Laboratories Share Price

147.95 -0.75 (-0.50%)
18-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.00
Dr. Reddys Lab 1267.80
Cipla 1355.80
Zydus Lifesciences 1074.30
Lupin 2327.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: